The news of CEO Jeff Ross resuming R&D leadership after John Barry's departure is relevant to Miromatrix as it directly involves the company's management. However, the impact on the stock price is expected to be neutral in the short term, as the company has stated that this transition will not affect their timelines and milestones, including the submission of a response to the FDA's clinical hold letter in H2 2023.